Overview

Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients

Status:
Not yet recruiting

Trial end date:
2021-09-30

Target enrollment:
0

Participant gender:
All

Summary

The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU (5-fluorouracil) or capecitabine. Therefore, a monocentric, partial prospective and partial retrospective trail was designed.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Jessa Hospital

Treatments:

Capecitabine
Fluorouracil

Criteria

Inclusion Criteria:

- Patients aged 18 years or older

- WHO (world health organization) classification 0,1 or 2

- A suspected start with 5-FU or capecitabine in mono or combination therapy

- The knowledge of the result of the geno and phenotyping before the start of the
treatment

Exclusion Criteria:

- Not meeting inclusion criteria

- Homozygote genotype or uracil 100 ng/ml or greater

- The lacking of the result of the geno and / or phenotyping before the start of
treatment

- Patients who received 5-FU or capecitabine in the past